Clinical Trial Update: Safety Study of GE-145 320 mg I/mL Injection vs. Iopamidol 370 mg I/mL in Elderly Subjects Undergoing Coronary Procedure [Phase 2]

View source ↗

Summary

Phase 2 safety study comparing GE-145 320 mg/mL injection to iopamidol 370 mg/mL in elderly undergoing coronary procedure; study completed with posted results.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Diabetes Mellitus
• Heart Failure
• Renal Insufficiency

Drugs mentioned

• GE-145 320 mg/mL Injection
• iopamidol 370 mg/mL (iopamidol)

Snippet

Sponsor: GE Healthcare | Conditions: Chronic Renal Insufficiency, Diabete Mellitus | Phase 2 | Status: COMPLETED | Results posted: 2014-05-02